However, since retatrutide targets multiple receptors, its side effect profile might differ slightly, though comprehensive long-term data are still forthcoming
Gastrointestinal side effects appear common, similar to other medicines in this treatment area
In Phase 2 trials (the TRIUMPH-2 study involving 338 participants over 48 weeks), the 12 mg dose of Retatrutide produced an average weight loss of 24.2%
Weight loss results vary by drug, with Rybelsus producing more modest losses (~6% in a year) and Foundayo and Wegovy producing results on par with injections (up to ~11%--14% in a year, respectively)
In retatrutide trials, people on placebo experienced minimal changes in hunger or number of calories consumed relative to the drug group
Glucagon-like peptide-1 receptor agonists during pregnancy and lactation